NSUN6 deficiency drives immune suppression in pancreatic cancer via the KDM5A-CCL2-macrophage axis.
Key Points
The research investigates how NSUN6 deficiency influences immune suppression in pancreatic cancer.
Analyzed the role of NSUN6 deficiency in pancreatic cancer models
Evaluated the KDM5A-CCL2 immune suppression axis
Assessed the impact of targeting NSUN6-CCL2 on ICB therapy sensitivity
NSUN6 deficiency correlates with increased immune suppression in pancreatic cancer
The KDM5A-CCL2 axis plays a crucial role in mediating this effect
Targeting the NSUN6-CCL2 pathway enhances responsiveness to immunotherapy.
Abstract
NSUN6 deficiency drives immune suppression through the m5C-KDM5A-CCL2 axis in PDAC. Targeting the NSUN6-CCL2 axis represents a promising strategy to sensitise PDAC to ICB therapy.